Vaccines and Related Biological Products
Advisory Committee June 10, 2021
Meeting Presentation

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: ocod@fda.hhs.gov and include 508 Accommodation and the title of the document in the subject line of your e-mail.
Adolescent COVID-19 Vaccination

Shannon Stokley, DrPH
Program Integration and Equity Unit
Vaccine Task Force

Meeting of the Vaccines and Related Biological Products Advisory Committee
June 10, 2021
Pfizer-BioNTech COVID-19 Vaccine recommendations in adolescents

- On May 12, 2021, the Advisory Committee on Immunization Practices (ACIP) voted to recommend Pfizer-BioNTech COVID-19 Vaccine for persons aged 12–15 years old under the FDA’s Emergency Use Authorization.
  - ACIP recommendations published in *Morbidity and Mortality Weekly Report*: [https://www.cdc.gov/mmwr/volumes/70/wr/mm7020e1.htm?s_cid=mm7020e1_w](https://www.cdc.gov/mmwr/volumes/70/wr/mm7020e1.htm?s_cid=mm7020e1_w)
  - CDC clinical considerations for use of the vaccine published at: [https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html)
Objectives

- Promote adolescent vaccination as quickly and equitably as possible through a multi-pronged approach.

- Leverage current COVID-19 vaccination infrastructure and adapt over time:
  - Early summer sprint (May–June)
  - Increase access (June–July)
  - Back-to-school campaign (July–September)
Stepwise approach to increasing vaccine access for adolescents

1. Augment existing infrastructure for vaccination
2. Strategically add providers that can reach adolescents
3. Apply school-focused strategies to ensure vaccination opportunities

<table>
<thead>
<tr>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
<th>September</th>
</tr>
</thead>
</table>

Adolescent vaccination
Approach for reaching adolescents
Augment existing public health infrastructure and add new channels

<table>
<thead>
<tr>
<th>Category</th>
<th>Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary care and other providers serving adolescents</td>
<td>• Utilize primary care as trusted providers to notify, schedule, and vaccinate their patients, including managing routine immunizations, particularly as students return to school</td>
</tr>
<tr>
<td>Pharmacies and HRSA sites¹</td>
<td>• Leverage broad pharmacy footprint to administer COVID-19 vaccine to adolescents rapidly, as with adults</td>
</tr>
<tr>
<td>School-based vaccination</td>
<td>• Partner with Federally Qualified Health Centers, pharmacies, public health, and adolescent provider networks to hold targeted programs to ensure equity and coverage, particularly as students return to school</td>
</tr>
</tbody>
</table>

¹ Health Resources and Services Administration (HRSA) sites including: Federally Qualified Health Centers (FQHCs), Rural Health Clinics, Community Health Centers
Consent

- The federal government does not have specific requirements for medical consent for vaccination.

- States/jurisdictions have medical consent laws that address the circumstances requiring and the processes for obtaining consent.
  - These laws vary across jurisdictions.
  - Providers may also be subject to policy requirements for consent within their own organizations.

- Sites administering vaccines should follow current state/jurisdictional policies and practices for other routine immunizations in this age group.

COVID-19 vaccination in the United States (June 7, 2021)

- **171,310,738 (51.6%)** people have received at least 1 dose of COVID-19 vaccine
- **3,430,741 (22.5%)** adolescents age 12–15 years have received at least 1 dose of COVID-19 vaccine

https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends
Coadministration

- COVID-19 vaccines and other vaccines **may now be administered without regard to timing**. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days.

- When deciding whether to coadminister other vaccines with COVID-19 vaccines, providers should consider:
  - If the patient is behind or at risk of becoming behind on recommended vaccines
  - Their risk of vaccine-preventable diseases (e.g., during an outbreak)
  - Reactogenicity profile of the vaccines

- If multiple vaccines are administered at a single visit, administer each injection in a different injection site.

Routine adolescent vaccines

- Updated coadministration recommendations may facilitate catch up vaccination of adolescents.

- As of June 6, 2021, overall Vaccines for Children Program provider orders (other than influenza) are down by **12.1 million doses** compared with 2019.

- This gap is largest in vaccines primarily given to adolescents.
  - Tdap vaccine – down **18.0%**
  - HPV vaccine – down **18.5%**
  - Meningococcal conjugate vaccine – down **12.2%**
Links for communication resources

Information for Parents and Adolescents
• **New web page:** COVID-19 Vaccines for Children and Teens
• **New fact sheet:** COVID-19 Vaccines for Preteens and Teens
• **New frequently asked questions:** Two new FAQs about the safety and benefits of COVID-19 vaccination for adolescents.
• **New myth-buster about menstrual cycles:** Question and answer
• **Myth-buster about infertility:** Question and answer
• **Key things to know:** Key Things to Know about COVID-19 Vaccines and About COVID-19 Vaccines
• **Vaccine information for specific groups:** COVID-19 Vaccine Information for Specific Groups

Information for Healthcare and Vaccine Providers
• **New pediatric toolkit:** Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit
• **New FAQs about consent for minors:** FAQs
• **New sample patient letter:** This sample letter
• **Recipient education page:** Vaccine Recipient Education

Information for Community Groups and Health Departments
• **Toolkit for community-based organizations:** Community-Based Organizations COVID-19 Vaccine Toolkit
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.